Charles River Laboratories International Inc (CRL) Stock AnalysisCRLStock AnalysisCharles River Laboratories International Inc

Charles River Laboratories International, Inc. is a drug development company. It provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and academic institutions around the globe accelerate their research and drug development efforts. Its Research Models and Services segment includes businesses that provide foundational tools that enable its clients to discover new molecules: Research Models and Research Model Services. Its Discovery and Safety Assessment (DSA) segment provides regulated and non-regulated DSA services to support the research, development, and regulatory-required safety testing of potential new drugs, including the in vitro, in vivo, and in silico studies, laboratory support services, and strategic non-clinical consulting and program management to support product development. Its Manufacturing Solutions segment includes Microbial Solutions and Biologics Solutions. It operates in the Healthcare sector (SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH industry).

Charles River Laboratories is a good buy right now due to its recent earnings performance and positive analyst upgrades. The current price is $291.5, which is below the analyst price target of $300, suggesting a potential upside of about 3%. Additionally, the company reported a strong Q2 EPS of $3.02, exceeding expectations and reflecting solid revenue growth of $1 billion, which is above the consensus estimate of $977.2 million. The main risk is the negative net income reported in recent quarters, with a net loss of $14.8 million in Q1 2026 and $1.48 million in Q2 2026, indicating ongoing financial challenges that investors should monitor closely.

16 analysts cover CRL: 8 rate it Buy, 8 Hold and 0 Sell. The average price target is 226.70.